Evofem Biosciences Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update
Evofem Biosciences, Inc. (Nasdaq: EVFM) reported strong growth for Q4 2021, with net product sales rising 109% to $3.6 million, largely due to a 73% increase in Phexxi units shipped. The company reduced its cash burn rate to $16.8 million from $32.0 million in Q3. Evofem also completed enrollment in its Phase 3 clinical trial for Phexxi, targeting new indications against chlamydia and gonorrhea, expecting to submit data to the FDA in early 2023. The total operating expenses for Q4 were $41.0 million, down from $45.1 million in Q3.
- Net product sales increased 109% to $3.6 million in Q4 2021.
- Cash burn rate reduced to $16.8 million in Q4 2021, down from $32.0 million in Q3.
- Completed enrollment in Phase 3 EVOGUARD trial for Phexxi targeting chlamydia and gonorrhea.
- Net loss attributable to common stockholders was $(52.6) million for Q4 2021, compared to $(74.1) million in Q3.
- Total operating expenses for the year increased to $175.0 million from $104.1 million in the prior year.
SAN DIEGO, March 3, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (Nasdaq: EVFM), a commercial stage biopharmaceutical company, today reported financial results for the three- and twelve-month periods ended December 31, 2021.
"In our first full year as a commercial company Evofem delivered strong growth, capped by an exceptional fourth quarter," said Saundra Pelletier, Chief Executive Officer. "Additionally, we achieved a significant milestone today: we completed enrollment in our Phase 3 clinical trial evaluating Phexxi for two potential new indications - the prevention of chlamydia and gonorrhea in women. Every sexually active woman is at risk to contract these STIs and there are no FDA-approved preventive measures; we believe this is a significant market opportunity for Evofem. We are eager to report top-line data in the second half of this year and submit to the FDA in the first half of 2023."
Fourth Quarter and Recent Highlights include:
- Net product sales increased
109% to$3.6 million in the fourth quarter of 2021, driven by a73% increase in Phexxi® (lactic acid, citric acid and potassium bitartrate) units shipped; - Reduced net cash burn rate to
$16.8 million in the fourth quarter of 2021 versus$32.0 million in Q3; - The U.S. Department of Labor and Health Resources and Services Administration updated guidelines in an effort to ensure women have access to all FDA-approved contraceptives, including Phexxi, at zero copay under the Affordable Care Act;
- Completed enrollment in EVOGUARD, the registrational Phase 3 trial evaluating Phexxi for the prevention of chlamydia and gonorrhea in women - two potential new indications;
- Secured a
$50 million equity line of credit; and, - Strengthened the balance sheet with aggregate gross proceeds of
$10 million from registered direct offerings of notes in January and March 2022.
Fourth Quarter Financial Results
For the three months ended December 31, 2021, net product sales were
Total operating expenses decreased to
- Research and development costs were
$8.7 million in both the fourth and third quarter of 2021, reflecting clinical trial expenses for the Phase 3 EVOGUARD trial of Phexxi for two potential new indications - prevention of urogenital chlamydia and gonorrhea in women. - Selling and marketing costs decreased
18% to$24.9 million in the fourth quarter of 2021 compared to$30.5 million in the prior quarter, due primarily to lower media expenses related to the "House Rules" DTC marketing campaign. - General and administrative costs increased
14% to$5.7 million , compared to$5.0 million in the prior quarter, primarily due to higher outside services and payroll-related expenses, including stock-based compensation.
Net loss attributable to common stockholders was
Full Year Financial Results
For the year ended December 31, 2021, net product sales were
Total operating expenses were
- Selling and marketing costs were
$113.2 million in 2021, compared to$56.5 million in the prior year. The increase largely reflects higher media and marketing costs in 2021, in particular direct-to-consumer activities including the "Get Phexxi" campaign and the ongoing "House Rules" campaign featuring celebrity ambassador Annie Murphy. - Research and development costs increased to
$33.1 million , compared to$17.1 million in the prior year period, due to higher clinical trial expenses for EVOGUARD, which was initiated in October 2020. - General and administrative costs decreased to
$24.7 million , compared to$30.1 million in the prior year, primarily reflecting lower consulting fees and reductions in payroll-related expenses, including stock-based compensation and headcount.
As a result, net loss attributable to common stockholders was
Liquidity
In the fourth quarter of 2021, Evofem strengthened its balance sheet with
At December 31, 2021, the Company had
Subsequent Material Events
The Company raised aggregate gross proceeds of approximately
Additionally in February 2022, Evofem secured a
Conference Call
As previously announced, the Evofem management team will host a conference call to discuss its financial results and business highlights as follows:
Date | Thursday March 3, 2022 |
Time | 4:30 p.m. ET (1:30 p.m. PT) |
Webcast (live and archived) | |
Dial-in numbers | (866) 503-5561 (U.S. toll-free) or (253) 336-2965 |
Passcode | 9976995 |
Please connect to the Company's website at least 15 minutes prior to the start of the event to download any software that may be required. If participating by phone, please also dial in approximately 15 minutes prior to the start of the call.
The webcast will be archived at https://evofem.investorroom.com/2021Q4YEResults. A telephone replay will be available for 24 hours after the call at (855) 859-2056 (U.S.) or (404) 537-3406 (International), conference ID 9976995.
About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (chlamydia and gonorrhea). The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com and evofem.com.
Phexxi® is a registered trademark of Evofem Biosciences, Inc.
Forward-Looking Statements
This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), and the Private Securities Litigation Reform Act of 1995 including, without limitation, statements related to the ongoing development of Phexxi, including related timelines and FDA submissions, and future growth of sales of Phexxi and the Company generally. Various factors could cause actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements, or that could impair the value of Evofem Biosciences' assets and business, are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 4, 2021 and subsequently filed Exchange Act Reports. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law. This press release contains estimates and other statistical data made by independent parties and by the Company relating to market size and growth and other data about its industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.
Investor Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775
(Tables follow)
EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEET DATA (Unaudited) (In thousands) | |||
December 31, 2021 | December 31, 2020 | ||
Cash and cash equivalents | $ 7,732 | $ 48,892 | |
Restricted cash | 5,056 | 22,559 | |
Trade accounts receivable, net | 6,449 | 1,067 | |
Total current liabilities | 137,663 | 77,283 | |
Total liabilities | 142,087 | 108,621 | |
Convertible and redeemable preferred stock | 4,740 | — | |
Total stockholders' equity (deficit) | (104,315) | 1,347 | |
EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except share and per share data) | |||||||
Quarter Ended December 31, | Year Ended December 31, | ||||||
2021 | 2020 | 2021 | 2020 | ||||
Product sales, net | $ 3,570 | $ 168 | $ 8,244 | $ 446 | |||
Operating expenses: | |||||||
Cost of goods sold | 1,755 | 151 | 4,055 | 468 | |||
Research and development | 8,659 | 5,946 | 33,129 | 17,050 | |||
Selling and marketing | 24,922 | 23,914 | 113,152 | 56,467 | |||
General and administrative | 5,652 | 6,008 | 24,709 | 30,085 | |||
Total operating expenses | 40,988 | 36,019 | 175,045 | 104,070 | |||
Loss from operations | (37,418) | (35,851) | (166,801) | (103,624) | |||
Other income (expense): | |||||||
Interest income | 1 | 17 | 15 | 169 | |||
Other expense | (1,211) | (1,072) | (4,732) | (2,082) | |||
Loss on issuance of financial instruments | — | — | — | (64,049) | |||
Change in fair value of financial instruments | (12,920) | (3,690) | (33,657) | 27,281 | |||
Total other expense, net | (14,130) | (4,745) | (38,374) | (38,681) | |||
Loss before income tax | (51,548) | (40,596) | (205,175) | (142,305) | |||
Income tax expense | (6) | (2) | (17) | (4) | |||
Net loss | (51,554) | (40,598) | (205,192) | (142,309) | |||
Series B-1 and B-2 convertible preferred stock deemed dividends | (1,047) | — | (1,047) | — | |||
Net loss attributable to common stockholders | $ (52,601) | $ (40,598) | $ (206,239) | $ (142,309) | |||
Net loss per share attributable to common stockholders, basic and diluted | $ (0.33) | $ (0.50) | $ (1.58) | $ (2.12) | |||
Weighted-average shares used to compute net loss per share, basic and diluted | 161,228,820 | 81,221,603 | 130,908,794 | 67,157,278 | |||
View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-reports-fourth-quarter-and-year-end-2021-financial-results-and-provides-corporate-update-301495311.html
SOURCE Evofem Biosciences, Inc.
FAQ
What were Evofem Biosciences' Q4 2021 financial results?
What is the cash burn rate for Evofem in Q4 2021?
What milestones did Evofem achieve in its clinical trials?
What is Evofem's net loss for Q4 2021?
What are Evofem's total operating expenses for 2021?
